Allurion Gastric Balloon Studies
Trusted Weight Loss Medical Team
Updated 26 February 2024 | Created 26 February 2024
- Cabellero A, Giardiello C, Oyola C, et al. The Swallowable Gastric Balloon: Global Experience in 5003 Consecutive Patients – The Largest Gastric Balloon Study in the World (IFSO 2023, Oral -325.) ‘’The largest study of the Allurion Gastric Balloon Program with 5003 consecutive patients confirms a TBWL of 14%, significantly improved metabolic parameters and consistent safety in diverse, global populations.
- Genco A, Giardiello C, Lucchese M, et al. Effects of New Procedureless Intragastric Balloon (Allurion) on Metabolic Syndrome and Pre-Diabetes. Italian Experience on 324 https://www.soard.org/article/S1550-7289(18)30693-2/pdf. ‘Allurion is safe and effective in inducing weight loss and results in a significant reduction in obesity-related metabolic diseases including metabolic syndrome and pre-diabetes’
- Raftopoulos Y, Tsechpenakis A, Davidson M E, Chapin K, Reardon C, McMillian U: The Swallowable Gastric Balloon Significantly Enhances an Intensive Lifestyle Intervention Program for Weight Loss: Final Short and Long Term Results up to 1 Year after Balloon Placement. https://epostersonline.com/asmbs2021/node/212. ‘Allurion IGB remains an independent and highly significant contributor of weight loss when added to a 1-year intensive lifestyle intervention. Furthermore, even after the passage of the Allurion balloon, 93% of weight loss was maintained at 1 year after placement’
- Rajkumar S and Raftopoulos Y: Procedureless Gastric Balloon Experience: A Focused Comparative Analysison BMI < vs. > 40 Subgroups (ASMBS 2023). ‘The Allurion Balloon is safe and effective in patients with a BMI >40, achieving over 20% TBWL at 6 months. It could be considered as a bridge to achieve preoperative weight loss before bariatric surgery or as a stand-alone method.
- Lenca R, Giardiello C, Schiano Di Cola R, et al: The Evolution of the Allurion Program for Long Term Weight Loss: From Virtual Monitoring to a Virtual Care Suite. https://www.karger.com/Article/Abstract/524649 (LBP4.16). ‘The Allurion Program with the VCS demonstrated excellent short and long-term efficacy for weight loss with very few adverse events’
